Brief oral Communication: Cpi-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis patients: update of manifest Phase 2 study
ESH eLearning, Francesco Passamonti,
348310
Brief oral Communication: Addition of Parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with Myelofibrosis
ESH eLearning, Abdulraheem Yacoub,
348267